Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Proxy Contest (June 2019)

58 slides from Progenics Pharmaceuticals's proxy contest presentation, Jun 20, 2019

  1. Slide 1: Change is Necessary to Drive Long-Term Success at Progenics Pharmaceuticals, Inc.

    Change is Necessary to Drive Long-Term Success at Progenics Pharmaceuticals, Inc. June 20, 2019 Velan Capital, L.P. – ALL RIGHTS RESERVED 1

  2. Slide 2: Disclosure & Disclaimer

    Disclosure & Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKE

  3. Slide 3: Table of Contents

    Table of Contents  Executive Summary  Performance, Stockholder & Governance Issues • Dismal Share Price Performance • Entrenchment-Minded Tactics & Egregious Governance Practices • Ineffective Oversight of Underqualified & Overpaid Management • Lack of Transparency  Operational Concerns • Botched

  4. Slide 4: Executive Summary

    Executive Summary Velan Capital, L.P. – ALL RIGHTS RESERVED 4

  5. Slide 5: This is a Rare Moment

    This is a Rare Moment  Stockholders have an opportunity to have their voices heard at the Progenics Pharmaceuticals, Inc. (“PGNX”, “Progenics”, or the “Company”) Annual Meeting to be held on Thursday, July 11th  The Company’s slogan is “Find, Fight, and Follow” -- we urge stockholders to “Find” th

  6. Slide 6: Situation Overview

    Situation Overview  Velan Capital, L.P. (“Velan Capital”), including the other participants in its call for change ("Velan", "Velan Group", or "we"), collectively own 9.3% of the outstanding shares of Progenics ― As the Company’s second largest stockholder, our goal is to maximize long-term value f

  7. Slide 7: Introduction to Velan Capital

    Introduction to Velan Capital  Velan Capital is a private investment partnership that strives to optimize long-term value creation ― All of its capital comes from its principals (not passive investors) ― We are truly long-term owners and not agents  Focus on undervalued healthcare companies with a

  8. Slide 8: Progenics’ Board: An Ugly Report Card

    Progenics’ Board: An Ugly Report Card Peter Crowley Michael Kishbauch (Chairman & (Chair of Nominating & Governance Mark Baker Committee & Member of (CEO & Director) Chair of Compensation Committee) Compensation Committee) Board Tenure 10+ years 5+ years ~10 years Total Stockholder Return (TSR) ~(45

  9. Slide 9: Squandered Opportunities

    Squandered Opportunities MIP-1095  MIP-1095 is a radiopharmaceutical that binds to prostate cancer cells to deliver highly targeted radiation  MIP-1095 was acquired in January 2013 with strong clinical data already in hand ― MIP-1095 laid dormant and remained undeveloped by Progenics until the lic

  10. Slide 10: Many Stockholders Share Velan’s Views

    Many Stockholders Share Velan’s Views  Numerous stockholders have reached out to Velan to express similar views and frustration regarding the Company’s lack of engagement and execution BOARD STRATEGY “The Board is truly a rubber stamp” “Never understood this company…have good assets but they don’t

  11. Slide 11: Velan’s Rationale for Change

    Velan’s Rationale for Change DISMAL SHARE PRICE PERFORMANCE GOVERNANCE ISSUES STOCKHOLDER & PERFORMANCE, ENTRENCHMENT-MINDED TACTICS & EGREGIOUS GOVERNANCE PRACTICES INEFFECTIVE OVERSIGHT OF UNDERQUALIFIED & OVERPAID MANAGEMENT LACK OF TRANSPARENCY BOTCHED COMMERCIAL EXECUTION OPERATIONAL CONCERNS Q

  12. Slide 12: Performance, Stockholder & Governance Issues

    Performance, Stockholder & Governance Issues Dismal Share Price Performance Velan Capital, L.P. – ALL RIGHTS RESERVED 12

  13. Slide 13: Stock Price Reflects Poor Execution

    Stock Price Reflects Poor Execution  PGNX has underperformed on both an absolute and relative basis over almost any time period ― Since 2009: when Messrs. Crowley and Baker joined the Board ― Since 2013: when Mr. Kishbauch joined the Board ― In more recent years while AZEDRA approval and launch wer

  14. Slide 14: Dramatic Relative Underperformance

    Dramatic Relative Underperformance PERFORMANCE VS. INDICES SINCE 2009 600% NASDAQ Biotech Index (Total Return) 500% NASDAQ Composite (Total Return) 400% PGNX 300% 200% 100% 0% (100%) Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 Jan-14 Jan-15 Jan-16 Jan-17 Jan-18 Jan-19 PERFORMANCE VS. ENDOCYTE SINCE LICENSE F

  15. Slide 15: Weak Track Records In Other Roles As Well

    Weak Track Records In Other Roles As Well  Mr. Kishbauch has served on three other public company boards in the past ten years ― Achillion Pharmaceuticals, Inc. – appointed as director in July 2004 (served as President & CEO until May 2013) ― Catabasis Pharmaceuticals, Inc. – appointed as director

  16. Slide 16: Exodus of Investors and Analysts

    Exodus of Investors and Analysts  Over the past five years, Progenics has had numerous notable healthcare investors exit their position ― 2015: Lord Abbett and Tiger Management ― 2016: Highbridge Capital ― 2017: Broadfin Capital and Wellington Management ― 2018: Baker Brothers, Fidelity Management

  17. Slide 17: Entrenchment-Minded Tactics & Egregious Governance Practices

    Performance, Stockholder & Governance Issues Entrenchment-Minded Tactics & Egregious Governance Practices Velan Capital, L.P. – ALL RIGHTS RESERVED 17

  18. Slide 18: Velan’s Outreach to Progenics Repeatedly Dismissed

    Velan’s Outreach to Progenics Repeatedly Dismissed  In 2018 and early 2019, Velan reached out to Progenics management on multiple occasions ― After a telephonic meeting in November 2018 and an in-person meeting in January 2019, the Company went silent despite Velan’s continued outreach  In Februar

  19. Slide 19: Progenics’ Invalidation of Our Nomination

    Progenics’ Invalidation of Our Nomination  The Company’s Bylaws require that only stockholders of record may nominate director candidates  On March 15, 2019, the date Velan submitted its nomination, it beneficially owned shares of Progenics in “street” name. While Velan is currently a stockholder

  20. Slide 20: Minimal Board Alignment & Ownership

    Minimal Board Alignment & Ownership  Collectively, the non-executive directors own approximately 0.06% of Progenics common stock(1)  Together, Messrs. Crowley and Kishbauch own ZERO shares of Progenics common stock(1) ― In 2018, Messrs. Crowley and Kishbauch earned $452,750 and $237,159, respectiv

  21. Slide 21: Board is Stale and Has Not Fulfilled Duties

    Board is Stale and Has Not Fulfilled Duties  Stale Board in need of fresh perspectives, more relevant track records and stockholder alignment ― Approximately 50% of the non-executive directors on the Board have lengthy tenure (over 10-20+ years) ― Directors Crowley (Chairman) and Baker (CEO) have t

  22. Slide 22: Ineffective Oversight of Underqualified & Overpaid Management

    Performance, Stockholder & Governance Issues Ineffective Oversight of Underqualified & Overpaid Management Velan Capital, L.P. – ALL RIGHTS RESERVED 22

  23. Slide 23: Ineffective Oversight of Unqualified Team

    Ineffective Oversight of Unqualified Team  Mark Baker’s biography ― “Mr. Baker, 63, Chief Executive Officer (“CEO”), joined us in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President, Corporate, in 2009 became President and a director, an

  24. Slide 24: Rewarding Perpetual Underperformance

    Rewarding Perpetual Underperformance Board’s Assessment of Performance Recent Events Performance Goals in Velan’s Commentary Metric 2017 & 2018  AZEDRA is a highly valuable asset with  AZEDRA PDUFA extended and potential to fill an unmet need for cancer subsequently approved in July 2018 patients

  25. Slide 25: Board Appears to Value Pay Over Science

    Board Appears to Value Pay Over Science  Does the Board regard pay as a more pressing matter than scientific advancement and clinical success? ― In 2017, Progenics’ Compensation Committee met more often than the Scientific Committee ― In 2016, the Compensation Committee met twice as often as the Sc

  26. Slide 26: Misaligned Compensation Program

    Misaligned Compensation Program  Under Mr. Crowley, as Chair of the Compensation Committee, and Mr. Kishbauch, as the only other member of the Compensation Committee, the Board has approved outsized pay while value has been destroyed, representing a clear misalignment of interests with stockholders

  27. Slide 27: Annual Incentives are 100% Discretionary

    Annual Incentives are 100% Discretionary  The annual bonus is based on four metrics that are vague and entirely discretionary  Each of the four targets required qualification from the Compensation Committee to justify payouts  Even with the exclusion of an impairment charge related to failure of

  28. Slide 28: Long-Term Incentives: 0% Performance-Based

    Long-Term Incentives: 0% Performance-Based  The Progenics Compensation Committee grants long-term incentive awards exclusively in the form of stock options without any performance-based conditions  Most shareholders, and leading proxy advisers ISS and Glass Lewis, don’t consider options to be perf

  29. Slide 29: Director Pay is Excessive and Egregious

    Director Pay is Excessive and Egregious  For 2018, the median of director pay at Progenics was $237,000, excluding Chairman Crowley, who received more than $452,000 in 2018  According to an ISS Board Practices Study in 2017, the median compensation for directors at Small Cap companies in the Pharm

  30. Slide 30: Lack of Transparency

    Performance, Stockholder & Governance Issues Lack of Transparency Velan Capital, L.P. – ALL RIGHTS RESERVED 30

  31. Slide 31: AZEDRA’s Manufacturing Mystery

    AZEDRA’s Manufacturing Mystery  AZEDRA’s manufacturing situation appears fine per the risk disclosures in the Company’s 2018 10-K but physician feedback and two recent developments raise serious related concerns ― Manufacturing facility acquisition in February 2019 for $8 million ― Contract manufac

  32. Slide 32: Lack of Regulatory Clarity

    Lack of Regulatory Clarity  Progenics has not been forthright with investors regarding the interactions with (and potential feedback from) the FDA on its Phase 2 clinical trial  Progenics announced its decision to move MIP-1095 into Phase 2 trial in October 2018  Progress is needed but why make t

  33. Slide 33: Velan’s Involvement Appears to be Making an Impact

    Velan’s Involvement Appears to be Making an Impact We believe Velan’s call for transparency has led to improvements in Progenics’ June corporate presentation but much more clarity and information is needed Image Source: Company filings. Velan Capital, L.P. – ALL RIGHTS RESERVED 33

  34. Slide 34: Operational Concerns: Botched Commercial Execution

    Operational Concerns Botched Commercial Execution Velan Capital, L.P. – ALL RIGHTS RESERVED 34

  35. Slide 35: Promises at Time of AZEDRA’s Approval

    Promises at Time of AZEDRA’s Approval  Upon its approval in July 2018, the Company stated that the nuclear, reimbursement and patient identification processes would take “weeks” not MORE THAN TEN MONTHS FDA APPROVAL PRESENTATION AND CONFERENCE CALL IN JULY 2018 “…I think you could view reimbursemen

  36. Slide 36: Overpromised and Underdelivered

    Overpromised and Underdelivered  In July 2018, Progenics stated: ― AZEDRA was “ready for commercialization” ― Reimbursement should be a “smoother, quicker process” for centers that participated in the trial ― Patient identification and dosing should take “eight weeks” ― Nuclear process should take

  37. Slide 37: AZEDRA: Comparison to Similar Products

    AZEDRA: Comparison to Similar Products  Progenics received approval for AZEDRA in July 2018 and dosed its first patient in June 2019  We could not find ONE other launch that took more than TEN MONTHS to dose a patient  With no Orange Book patents, each day AZEDRA was delayed was a day lost of its

  38. Slide 38: Physician Perspectives & Patient Impact

    Physician Perspectives & Patient Impact  Physician feedback regarding AZEDRA’s launch illustrates the lack of experience and oversight at Progenics ― Progenics even stated on its Q1 2019 earnings call “we're gaining experience with the drug”  KOLs and physicians we spoke with heard from the Compan

  39. Slide 39: Questionable Clinical Program Decision Making

    Operational Concerns Questionable Clinical Program Decision Making Velan Capital, L.P. – ALL RIGHTS RESERVED 39

  40. Slide 40: MIP-1095: Blind But Now I See

    MIP-1095: Blind But Now I See  In the six years since acquiring MIP-1095, arguably its most valuable asset, we believe the Board has shown continual neglect and a lack of urgency STANDING STILL AND WATCHING THE COMPETITION PASS BY  It appears to have taken the foresight of Endocyte and its acquisi

  41. Slide 41: AZEDRA: Advanced at Glacial Pace

    AZEDRA: Advanced at Glacial Pace  Progenics acquired AZEDRA from MIP in January 2013 ― In November 2013, Progenics announced it was “relaunching the registrational trial” ― In January 2015, Progenics noted that it had dosed the first subject since trial was resumed  Similar to its commercial strug

  42. Slide 42: Inefficient Financial Management

    Operational Concerns Inefficient Financial Management Velan Capital, L.P. – ALL RIGHTS RESERVED 42

  43. Slide 43: Poor Budget Containment / Enforcement

    Poor Budget Containment / Enforcement  The Company has not disclosed numerous financial details that we believe would help analysts and investors assess the Progenics opportunity and monitor performance  However, based on available disclosures, we can symbolically observe wasteful spending  For e

  44. Slide 44: Capital Allocation Concerns

    Capital Allocation Concerns  In our meeting on March 25, 2019 with Messrs. Crowley and Baker, Mr. Baker launched into a series of flawed statements around the purported drawbacks of certain nondilutive financing alternatives and seemed to express a preference for extensive (and dilutive) equity off

  45. Slide 45: Persistent & Unnecessary Dilution

    Persistent & Unnecessary Dilution  Since Chairman Crowley’s reign began in 2009, Progenics has completed equity financings raising more than $200 million, which currently represents over 50% of the Company’s fully-diluted equity value ― In 2018 alone, ~$100 million of dilutive equity was raised  F

  46. Slide 46: Conclusion

    Conclusion Velan Capital, L.P. – ALL RIGHTS RESERVED 46

  47. Slide 47: Now is the Time for Much Needed Change and Accountability at Progenics

    Now is the Time for Much Needed Change and Accountability at Progenics  We believe Progenics’ value resides primarily with its RELISTOR royalties, approved drug AZEDRA, net cash, and pipeline (particularly the 1095 and PyL programs)  However, it is critical to efficiently direct appropriate resour

  48. Slide 48: Your Choice and Voice Can Be Heard

    Your Choice and Voice Can Be Heard  We believe change is desperately needed at Progenics  The first step toward achieving this change is by making your voices heard at the upcoming Annual Meeting by voting AGAINST the re-election of Messrs. Crowley and Kishbauch  By voting AGAINST Mr. Crowley as

  49. Slide 49: Velan’s Approach to Board Duties

    Velan’s Approach to Board Duties  Governance ― Instill culture of accountability, alignment, and analytical rigor ― Proper assessment of management based on performance relative to ambitious corporate goals ― Long-term, performance-based incentive plans, stock ownership requirements ― Scrutinize ma

  50. Slide 50: Weighing Key Takeaways

    Weighing Key Takeaways Compelling Value Proposition Accountability, management oversight and stockholder alignment tip the scale in favor of enduring success Velan Capital, L.P. – ALL RIGHTS RESERVED 50

  51. Slide 51: Vote to Protect the Value of Your Investment on the GREEN Proxy Card

    Vote to Protect the Value of Your Investment on the GREEN Proxy Card TODAY Vote AGAINST Messrs. Crowley and Kishbauch Given the Lack of Accountability and Stockholder Alignment, and Egregious Corporate Governance Practices Vote AGAINST the Compensation Proposal Given the Persistent Underperformance

  52. Slide 52: Appendix

    Appendix Velan Capital, L.P. – ALL RIGHTS RESERVED 52

  53. Slide 53: Background to Velan’s Solicitation

    Background to Velan’s Solicitation  After having followed the Company and its predecessors for years, Velan initiated its current investment in July 2018 and initially interacted with representatives of the Company during a telephonic conversation on November 29, 2018.  Over the ensuing months, Ve

  54. Slide 54: Background to Velan’s Solicitation (Cont’d)

    Background to Velan’s Solicitation (Cont’d)  On March 27, 2019, the Participating Stockholders crossed the five percent (5%) ownership threshold, thereby triggering their obligation under the Securities Exchange Act of 1934 (the “Exchange Act”) to file a Schedule 13D within 10 calendar days.  On A

  55. Slide 55: Background to Velan’s Solicitation (Cont’d)

    Background to Velan’s Solicitation (Cont’d)  On April 24, 2019, Messrs. Venkataraman, Heck, Sarpangal and Cooke held separate in-person meetings in New York City with Mr. Kishbauch and Ms. Williams to discuss their respective qualifications for serving on the Board. During Mr. Venkataraman’s meetin

  56. Slide 56: Velan: Proposed Nominees

    Velan: Proposed Nominees Bala Venkataraman: Mr. Venkataraman is an experienced operating executive and investor in the specialty pharmaceutical industry and is currently a Partner at Avego Healthcare Capital, LLC. Since 2013, Mr. Venkataraman has launched, financially sponsored, and successfully bui

  57. Slide 57: Velan: Proposed Nominees (Cont’d)

    Velan: Proposed Nominees (Cont’d) Matthew Heck: Mr. Heck is the original founder, CEO and a member of the Board of Directors of Sentynl Therapeutics, Inc. and has 25 years of experience in the pharmaceutical industry. At Sentynl, he has been the key driver behind M&A, financing, hiring and managing

  58. Slide 58: Velan: Proposed Nominees (Cont’d)

    Velan: Proposed Nominees (Cont’d) Ryan Melkonian: Mr. Melkonian is the founder and managing partner of Melkonian Capital Management. With 25 years of investment experience, Ryan is responsible for overseeing the firm’s investment portfolio (private equity, real estate and public markets) and chairs

Progenics Pharmaceuticals — Proxy Contest (June 2019) on 6ix